Related Experiment Videos
Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.
Barry S Komm1, Yogendra P Kharode, Peter V N Bodine
1Wyeth Research, Women's Health Research Institute, Collegeville, Pennsylvania 19426, USA. kommb@wyeth.com
Endocrinology
|June 18, 2005
Summary
Bazedoxifene acetate, a novel selective estrogen receptor modulator, shows promise for osteoporosis treatment. Preclinical studies indicate it enhances bone density and strength with potentially fewer uterine and vasomotor side effects than existing therapies.
Area of Science:
- Pharmacology
- Endocrinology
- Bone Biology
Background:
- Selective estrogen receptor modulators (SERMs) are crucial for managing conditions like osteoporosis.
- Understanding the preclinical profile of novel SERMs is essential for therapeutic development.
Purpose of the Study:
- To evaluate the preclinical characteristics of bazedoxifene acetate.
- To assess its efficacy in bone health and its impact on uterine and central nervous system pathways.
Main Methods:
- In vitro assays for estrogen receptor binding and cell proliferation.
- In vivo studies in rat models for bone mineral density, bone strength, uterine effects, and vasomotor activity.
Main Results:
- Bazedoxifene acetate demonstrated significant bone mineral density and strength increases in ovariectomized rats.
- It showed reduced uterine wet weight increase and less endometrial hypertrophy compared to other agents.
- Bazedoxifene did not stimulate breast cancer cell proliferation and had minimal impact on vasomotor responses.
Conclusions:
- Bazedoxifene acetate exhibits a promising preclinical profile for osteoporosis treatment.
- Its potential for reduced uterine and vasomotor side effects warrants further clinical investigation.